Atorvastatin Recall Highlights FDA Inspection Challenges Abroad

The recall of thousands of atorvastatin bottles due to manufacturing defects highlights ongoing issues with overseas drug production and FDA oversight, risking reduced drug efficacy and increased cardiovascular risks for millions of patients.